Recent advances in neoantigen vaccines for treating non‐small cell lung cancer

The breakthrough of programmed cell death protein 1 (PD‐1) blockade therapy has changed the clinical treatment of non‐small cell lung cancer (NSCLC) in the past few years. The success of PD‐1 blockade therapy has been attributed to high tumor mutation burden and high immunogenicity of lung cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shu, Chen, Fungjun, Xu, Mingyuan, Liu, Baorui, Wang, Lifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693939/
https://www.ncbi.nlm.nih.gov/pubmed/37905603
http://dx.doi.org/10.1111/1759-7714.15126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693939/
https://www.ncbi.nlm.nih.gov/pubmed/37905603
http://dx.doi.org/10.1111/1759-7714.15126

Ejemplares similares